Company: PFSA
Filing Date: 2025-10-29
Form Type: 424B3
Source: 0001213900-25-103174
Chunk: 179

Company: Profusa, Inc.
Filing Date: 2025-10-29
Form: 424B3
Chunk 179
---
 cash generated from the
business combination includes an initial net $9 million in PIPE proceeds from the first tranche of a convertible note, along with
an expected $2 million additional tranche from the PIPE convertible note to be received within the nine months ended September 30,
2025. Until we generate sufficient operating cash flow to cover our operating expenses, working capital needs and planned capital expenditures,
or if circumstances evolve differently than anticipated, we expect to utilize a combination of equity and debt financing to fund any future
capital needs. If we raise funds by issuing equity securities, dilution to stockholders may result. Any equity securities issued may also
provide for rights, preferences, or privileges senior to those of holders of common stock. If we raise funds by issuing debt securities,
these debt securities may have rights, preferences, and privileges senior to those of common stockholders. The terms of debt securities
or borrowings could impose significant restrictions on our operations. The capital markets are currently experiencing, and may continue
to experience in the future, periods of upheaval that could impact the availability and cost of equity and debt financing.

Our principal uses of cash
in recent periods have been funding our research and development activities and other personnel cost. Near-term capital requirements through
June 30, 2025 leading to and supporting initial commercialization are estimated to total approximately $7.3 million and include
further research and development to enable us to obtain the required regulatory approvals, manufacturing, commercialization and wide-scale
marketing for our Lumee Oxygen and Lumee Glucose devices. Our future capital requirements will depend on many factors, including our revenue
growth rate, the timing and the amount of cash received from our customers, the expansion of sales and marketing activities, the timing
and extent of spending to support development efforts. In the future, we may enter into arrangements to acquire or invest in complementary
businesses, products, and technologies. For any periods after the twelve months subsequent to the filing of these financial statements
as of June 30, 2025, we may be required to seek additional equity or debt financing. In the event that we require additional financing
we may not be able to raise such financing on acceptable terms or at all. If we are unable to raise additional capital or generate cash
flows necessary to continue our research and development and invest in continued innovation, we may not be able to compete successfully,
which would harm our business, results of operations, and financial condition. If adequate funds are not available, we may need